The stock of BeiGene, Ltd. (NASDAQ:BGNE) is a huge mover today! The stock decreased 3.74% or $7.47 during the last trading session, reaching $192.44. About 434,609 shares traded or 10.14% up from the average. BeiGene, Ltd. (NASDAQ:BGNE) has declined 22.42% since December 4, 2018 and is downtrending. It has underperformed by 22.42% the S&P500.
The move comes after 7 months negative chart setup for the $11.69B company. It was reported on Dec, 4 by Barchart.com. We have $182.82 PT which if reached, will make NASDAQ:BGNE worth $584.25M less.
Analysts await BeiGene, Ltd. (NASDAQ:BGNE) to report earnings on February, 26. They expect $-4.00 EPS, up 11.50 % or $0.52 from last year’s $-4.52 per share. After $-5.11 actual EPS reported by BeiGene, Ltd. for the previous quarter, Wall Street now forecasts -21.72 % EPS growth.
BeiGene, Ltd. (NASDAQ:BGNE) Ratings Coverage
Among 6 analysts covering BeiGene (NASDAQ:BGNE), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BeiGene has $23000 highest and $20000 lowest target. $216.86’s average target is 12.69% above currents $192.44 stock price. BeiGene had 11 analyst reports since July 15, 2019 according to SRatingsIntel. The stock of BeiGene, Ltd. (NASDAQ:BGNE) has “Outperform” rating given on Wednesday, November 13 by Cowen & Co. Guggenheim maintained the stock with “Buy” rating in Friday, November 15 report. Maxim Group maintained the stock with “Buy” rating in Monday, November 4 report. The firm has “Buy” rating by Bank of America given on Monday, November 18. The firm earned “Overweight” rating on Monday, November 4 by JP Morgan. The firm has “Overweight” rating given on Monday, August 12 by Morgan Stanley. The firm has “Overweight” rating by Morgan Stanley given on Friday, October 11.
More notable recent BeiGene, Ltd. (NASDAQ:BGNE) news were published by: Fool.com which released: “Buy These 2 Stocks to Access China’s Huge Healthcare Market – The Motley Fool” on November 06, 2019, also Investorplace.com with their article: “This $2.7 Billion Deal Is a Shot Across the Bow for Big Pharma – Investorplace.com” published on November 08, 2019, Finance.Yahoo.com published: “BeiGene (NASDAQ:BGNE) Has Debt But No Earnings; Should You Worry? – Yahoo Finance” on August 20, 2019. More interesting news about BeiGene, Ltd. (NASDAQ:BGNE) were released by: Nasdaq.com and their article: “2 Stocks to Buy If You’re Worried About a Recession – Nasdaq” published on November 22, 2019 as well as Seekingalpha.com‘s news article titled: “FTC signs off on Amgen/BeiGene deal – Seeking Alpha” with publication date: December 02, 2019.
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops molecularly-targeted and immuno-oncology drugs for the treatment of cancer. The company has market cap of $11.69 billion. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations. It currently has negative earnings. The Company’s preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.